L-Serine

Pharmacology & Research

L-serine is a non-essential amino acid the body makes for itself from a glycolytic intermediate (3-phosphoglycerate) and from glycine, so a healthy, protein-fed person is essentially never short of it. Its therapeutic interest is therefore not “top up a common shortfall” but a handful of specific situations where serine supply or serine-derived lipids go wrong: inborn errors of serine synthesis, a rare inherited neuropathy (HSAN1), and — more speculatively — ALS, developmental NMDA-receptor disorders and diabetic nerve damage. The strongest data are in rare, genetically defined populations where supplementation corrects a real deficit; the popular “neuroprotective supplement” framing rests largely on preclinical work and one hypothesis (that dietary L-serine blocks misincorporation of the cyanobacterial toxin BMAA). Because L-serine competes with other neutral amino acids for transport into the brain, very high doses can paradoxically lower other amino acids — dose and context matter more than the fact of taking it.

1. Serine-deficiency syndromes (3-PGDH)

Defects in the three enzymes that synthesise L-serine — most commonly 3-phosphoglycerate dehydrogenase (3-PGDH) — cause congenital microcephaly, severe psychomotor retardation and intractable seizures, and are unusual among neurometabolic diseases in being treatable ^{2Reference 2de Koning et al. · 2004ReviewSerine-deficiency syndromes — reviewView study →}. Oral L-serine, often combined with glycine, can arrest otherwise drug-resistant seizures: in one 4½-year-old with 3-PGDH deficiency, seizures responded only to L-serine and glycine supplementation ^{3Reference 3Coşkun et al. · 2009Case reportCoşkun, T., Aydin, H. I., Kiliç, M., et al. (2009). 3-phosphoglycerate dehydrogenase deficiency: a case report of a treatable cause of seizures — case report. The Turkish Journal of Pediatrics. https://pubmed.ncbi.nlm.nih.gov/20196394/View study →}. This is a genuine repletion benefit — the supplement replaces a metabolite the patient cannot make — but it applies to a rare, genetically defined group, and dosing must be watched: in two siblings, very high-dose serine (1400 mg/kg/day) arrested head growth (reversible on dose reduction) and lowered CSF methionine, isoleucine and ornithine through competition for transport ^{4Reference 4Häusler et al. · 2001Case reportPhenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings — case reportView study →}.

Gap: benefit is confined to people with a proven biosynthetic defect; no RCT (evidence is case reports/series), and the therapeutic window is dose-sensitive.

2. Hereditary neuropathy (HSAN1)

HSAN1, caused by SPTLC1/SPTLC2 mutations, produces neurotoxic 1-deoxysphingolipids because the mutant enzyme uses alanine instead of serine; loading the system with L-serine pushes the enzyme back toward its normal substrate. In a randomised, placebo-controlled trial (n=18, 400 mg/kg/day for 1 year with an open-label second year), the L-serine group improved on the Charcot-Marie-Tooth Neuropathy Score relative to placebo (−1.5 units, 95% CI −2.8 to −0.1), with reduced plasma deoxysphingolipids; the authors graded it Class I evidence that high-dose L-serine slows disease progression ^{1Reference 1Fridman et al. · 2019RCTRandomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1 — randomised controlled trialView study →}. An iPSC model of the same disease shows L-serine-responsive neurite deficits, supporting the mechanism ^{12Reference 12Clark et al. · 2021In vitroAn iPSC model of hereditary sensory neuropathy-1 reveals L-serine-responsive deficits in neuronal ceramide — in vitro/iPSCView study →}.

Gap: a single small trial (16 completers) in a rare disease; “slows progression” is not “reverses,” and the 400 mg/kg/day dose is far above ordinary supplemental use.

3. GRIN-related encephalopathy

GRIN disorders are rare developmental encephalopathies caused by variants in NMDA-receptor subunit genes; L-serine is a precursor of D-serine, an NMDA co-agonist, giving a rationale in loss-of-function variants. A phase 2A, open-label, single-arm trial (NCT04646447; n=24, ages 2–18, 52 weeks) reported improvements in several Vineland adaptive-behaviour subdomains for the cohort and a significant Bayley cognitive gain in the more severely affected group ^{8Reference 8Juliá-Palacios et al. · 2024RCTL-serine treatment in patients with GRIN-related encephalopathy: a phase 2A, non-randomized study — clinical trialView study →}.

Gap: no control group and no blinding, so developmental gains cannot be separated from natural change or expectation effects; hypothesis-generating only.

4. ALS

The ALS rationale is the BMAA hypothesis: the cyanobacterial non-protein amino acid β-N-methylamino-L-alanine can be misincorporated into proteins in place of L-serine, causing misfolding and aggregation, and excess L-serine inhibits that misincorporation in vitro ^{9Reference 9Dunlop et al. · 2013In vitroThe non-protein amino acid BMAA is misincorporated into human proteins in place of L-serine causing protein misfolding and aggregation — in vitroView study →}. A randomised, double-blind phase I trial (n=20; 0.5–15 g twice daily for 6 months) found L-serine generally safe and, against historical placebo controls, it “did not appear to accelerate” functional decline ^{5,6Reference 5Levine et al. · 2017RCTPhase I clinical trial of safety of L-serine for ALS patients — randomised controlled trial (phase I)View study →Reference 6Bradley et al. · 2018Clinical trialStudies of Environmental Risk Factors in Amyotrophic Lateral Sclerosis (ALS) and a Phase I Clinical Trial of L-Serine — clinical trial (phase I)View study →}. Independent review (ALSUntangled 38) judged the evidence preliminary ^{7Reference 7ALSUntangled 38: L-serine · 2017ReviewALSUntangled 38: L-serine (2017) — review. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. https://pubmed.ncbi.nlm.nih.gov/27894192/View study →}.

Gap: this is a safety/tolerability study, not an efficacy trial — comparison was to historical controls, three patients died during the trial, and the underlying BMAA-causation hypothesis remains unproven.

5. Diabetic peripheral neuropathy

Low serine and accumulation of neurotoxic 1-deoxysphingolipids are implicated in diabetic peripheral neuropathy, and human genetic evidence (a 2026 preprint) links the serine-biosynthesis pathway to the disease ^{11Reference 11Fridman et al. · 2026Human genetic evidence links serine biosynthesis to diabetic peripheral neuropathy — genetic association study (preprint). medRxiv. https://pubmed.ncbi.nlm.nih.gov/42326776/View study →}. In db/db mice, 6 months of oral L-serine (5–20% of diet) suppressed toxic 1-deoxysphingolipids and improved functional/sensory measures, though structural axon degeneration still progressed ^{10Reference 10Xia et al. · 2023AnimalLong-term effects of l-serine supplementation upon a mouse model of diabetic neuropathy — animal studyView study →}.

Gap: entirely preclinical plus genetic association — no completed human efficacy trial, and even in mice the structural protection was incomplete.

Mechanisms

Target / pathway	Effect	Relevant to
One-carbon (folate) metabolism	Donates carbon units for nucleotide and methyl-group synthesis	General metabolism; rapidly dividing tissue
Phospholipid / sphingolipid synthesis	Precursor of phosphatidylserine and sphingoid bases	HSAN1, diabetic neuropathy
Serine palmitoyltransferase substrate	Excess serine outcompetes alanine, lowering neurotoxic 1-deoxysphingolipids	HSAN1, diabetic neuropathy
Glycine + cysteine synthesis	Metabolic precursor	Serine-deficiency syndromes
D-serine → NMDA receptor co-agonist	Supplies co-agonist for NMDA-receptor signalling	GRIN disorders; CNS signalling
Neutral amino-acid transport (LAT1)	Competes with Met/Ile/other neutral AAs at the blood–brain barrier	High-dose safety caveat

Pharmacokinetics

Oral L-serine is absorbed through intestinal neutral-amino-acid transporters and enters the general amino-acid pool; the body also synthesises it endogenously, so plasma levels are tightly regulated and the plasma half-life of a dose is short (on the order of hours, as for dietary amino acids generally). The decision-relevant PK fact is transport competition: L-serine shares carriers with other large neutral amino acids at the blood–brain barrier, so very high doses can lower CSF methionine, isoleucine and ornithine — this is why high-dose regimens are titrated and monitored rather than simply maximised ^{4Reference 4Häusler et al. · 2001Case reportPhenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings — case reportView study →}. Studied oral doses span an enormous range, from grams/day up to 400 mg/kg/day (HSAN1) and 15 g twice daily (ALS).

Clinical trials

Registered human trials of L-serine are few and concentrated in rare disease: a completed HSAN1 RCT (NCT01733407), a completed ALS phase I trial, and a completed GRIN-encephalopathy phase 2A study (NCT04646447), with diabetic-neuropathy work still at the preclinical/genetic stage. As an unpatentable amino acid, L-serine attracts little industry-funded late-phase trial activity.

Last checked: July 2026.

Dietary Sources

L-serine is non-essential: healthy adults synthesise it from the glycolytic intermediate 3-phosphoglycerate and from glycine, and dietary protein supplies the rest, so deficiency from diet essentially does not occur in the general population. It is abundant in ordinary protein foods rather than concentrated in a few sources.

Food group	Representative sources	Note
Animal protein	Eggs, meat, poultry, fish, dairy	High-quality, serine-rich protein
Legumes / soy	Soybeans, tofu, lentils, peanuts	Strong plant sources
Nuts & seeds	Almonds, walnuts, sesame, sunflower	Good density
Grains	Wheat, oats (whole)	Refining lowers overall protein/amino-acid content

Because the body makes its own, “getting enough serine” is not a practical dietary concern; the therapeutic doses used in trials (grams per day to hundreds of mg/kg) far exceed anything obtainable from food and are pharmacological, not nutritional.

Intake & Dosage

There is no RDA/AI and no Tolerable Upper Intake Level for L-serine — it is a non-essential amino acid, not a nutrient with a Dietary Reference Intake. Supplemental doses studied in research vary enormously by indication:

• HSAN1: 400 mg/kg/day (≈28 g/day for a 70 kg adult), medically supervised.
• ALS (phase I): 0.5–15 g twice daily (up to 30 g/day).
• Serine-deficiency syndromes: weight-based dosing, often with glycine, titrated to effect and monitored (excessive doses have caused harm).

For healthy adults there is no established or recommended supplemental dose, because no benefit has been demonstrated in serine-replete people. As an amino acid competing for transport, L-serine is generally taken in divided doses. These are doses studied in research, not a personal recommendation.

Safety

L-serine is well tolerated as a dietary component and was “generally safe” in the ALS phase I trial and the HSAN1 RCT at high doses ^{1,5Reference 1Fridman et al. · 2019RCTRandomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1 — randomised controlled trialView study →Reference 5Levine et al. · 2017RCTPhase I clinical trial of safety of L-serine for ALS patients — randomised controlled trial (phase I)View study →}. The most common adverse effects at high doses are gastrointestinal (two ALS participants withdrew for GI problems) ^{5Reference 5Levine et al. · 2017RCTPhase I clinical trial of safety of L-serine for ALS patients — randomised controlled trial (phase I)View study →}. The dose-limiting concern is transport competition: high-dose serine competitively lowers other neutral amino acids (methionine, isoleucine, ornithine) at the blood–brain barrier, and in an infant given ~1400 mg/kg/day this coincided with arrested head growth that reversed on dose reduction ^{4Reference 4Häusler et al. · 2001Case reportPhenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings — case reportView study →} — a caution specific to very high, weight-based dosing. People with renal impairment or on amino-acid-restricted diets should be cautious, and high-dose use belongs under medical supervision.

Pregnancy & lactation

Verdict: not established. L-serine as a normal dietary amino acid is part of every pregnancy, but supplemental high-dose use has not been evaluated for safety in pregnancy or lactation. High-dose supplementation should be avoided in pregnancy/lactation without medical supervision.

Scope disclosure (REQUIRED honesty):

• Interactions assessed? Partially. No specific drug-interaction studies exist; the main pharmacological interaction is competition with other neutral amino acids for transport (relevant to amino-acid-based therapies and CNS amino-acid balance). No CYP-based interactions are expected for an endogenous amino acid.
• Pregnancy/lactation assessed? No — not evaluated for supplemental use; treated as not established above.
• Upper Limit (UL) established? No UL set. Absence of a UL does not imply unlimited intake is safe — high weight-based doses have caused harm.

References